MX2022002850A - Formulaciones de anticuerpos anti-il-23p19. - Google Patents
Formulaciones de anticuerpos anti-il-23p19.Info
- Publication number
- MX2022002850A MX2022002850A MX2022002850A MX2022002850A MX2022002850A MX 2022002850 A MX2022002850 A MX 2022002850A MX 2022002850 A MX2022002850 A MX 2022002850A MX 2022002850 A MX2022002850 A MX 2022002850A MX 2022002850 A MX2022002850 A MX 2022002850A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain amino
- antibody
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897930P | 2019-09-09 | 2019-09-09 | |
| PCT/IB2020/058347 WO2021048743A1 (en) | 2019-09-09 | 2020-09-09 | Anti-il-23p19 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002850A true MX2022002850A (es) | 2022-04-06 |
Family
ID=72615913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002850A MX2022002850A (es) | 2019-09-09 | 2020-09-09 | Formulaciones de anticuerpos anti-il-23p19. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210070852A1 (enExample) |
| EP (1) | EP4028419A1 (enExample) |
| JP (2) | JP2022547162A (enExample) |
| KR (1) | KR20220062359A (enExample) |
| CN (1) | CN114340674A (enExample) |
| AU (1) | AU2020345071A1 (enExample) |
| BR (1) | BR112022003169A2 (enExample) |
| CA (1) | CA3147328A1 (enExample) |
| CL (1) | CL2024002086A1 (enExample) |
| IL (1) | IL291131A (enExample) |
| MX (1) | MX2022002850A (enExample) |
| PH (1) | PH12022550558A1 (enExample) |
| TW (2) | TW202535466A (enExample) |
| WO (1) | WO2021048743A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791734A1 (ru) | 2015-02-04 | 2018-01-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения воспалительных заболеваний |
| CA3164996A1 (en) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| WO2023019556A1 (zh) * | 2021-08-20 | 2023-02-23 | 齐鲁制药有限公司 | 一种高浓度抗her2的抗体制剂及其用途 |
| WO2023244746A1 (en) * | 2022-06-15 | 2023-12-21 | Abbvie Inc. | Risankizumab compositions |
| CA3263219A1 (en) * | 2022-10-21 | 2024-04-25 | Chong Kun Dang Pharmaceutical Corp. | STABLE ANTIBODY COMPOSITION |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
| WO2025137347A1 (en) * | 2023-12-20 | 2025-06-26 | Abbvie Inc. | High concentration risankizumab formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU695129B2 (en) * | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| PL1896073T3 (pl) * | 2005-06-30 | 2013-08-30 | Janssen Biotech Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
| US8263748B2 (en) * | 2008-08-27 | 2012-09-11 | Schering Corporation | Lyophilized formulations of engineered anti-IL-23p19 antibodies |
| US9265834B2 (en) * | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| AP3953A (en) * | 2010-11-04 | 2016-12-22 | Boehringer Ingelheim Int | Anti-IL-23 antibodies |
| JP6293120B2 (ja) * | 2012-05-03 | 2018-03-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ＩＬ−２３ｐ１９抗体 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EA201791734A1 (ru) * | 2015-02-04 | 2018-01-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения воспалительных заболеваний |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| JP2019536756A (ja) * | 2016-10-14 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２３ａ抗体を用いて疾患を処置する方法 |
| WO2019246271A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
-
2020
- 2020-09-08 TW TW113142787A patent/TW202535466A/zh unknown
- 2020-09-08 US US17/014,399 patent/US20210070852A1/en active Pending
- 2020-09-08 TW TW109130792A patent/TW202123965A/zh unknown
- 2020-09-09 CN CN202080062754.3A patent/CN114340674A/zh active Pending
- 2020-09-09 MX MX2022002850A patent/MX2022002850A/es unknown
- 2020-09-09 AU AU2020345071A patent/AU2020345071A1/en active Pending
- 2020-09-09 BR BR112022003169A patent/BR112022003169A2/pt unknown
- 2020-09-09 JP JP2022515471A patent/JP2022547162A/ja active Pending
- 2020-09-09 KR KR1020227011838A patent/KR20220062359A/ko active Pending
- 2020-09-09 CA CA3147328A patent/CA3147328A1/en active Pending
- 2020-09-09 PH PH1/2022/550558A patent/PH12022550558A1/en unknown
- 2020-09-09 WO PCT/IB2020/058347 patent/WO2021048743A1/en not_active Ceased
- 2020-09-09 EP EP20776232.9A patent/EP4028419A1/en active Pending
-
2022
- 2022-03-06 IL IL291131A patent/IL291131A/en unknown
-
2024
- 2024-07-10 CL CL2024002086A patent/CL2024002086A1/es unknown
-
2025
- 2025-07-30 JP JP2025127141A patent/JP2025163108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114340674A (zh) | 2022-04-12 |
| JP2025163108A (ja) | 2025-10-28 |
| AU2020345071A1 (en) | 2022-03-24 |
| TW202535466A (zh) | 2025-09-16 |
| CL2024002086A1 (es) | 2025-01-10 |
| BR112022003169A2 (pt) | 2022-05-17 |
| KR20220062359A (ko) | 2022-05-16 |
| CA3147328A1 (en) | 2021-03-18 |
| WO2021048743A1 (en) | 2021-03-18 |
| EP4028419A1 (en) | 2022-07-20 |
| PH12022550558A1 (en) | 2023-02-20 |
| IL291131A (en) | 2022-05-01 |
| TW202123965A (zh) | 2021-07-01 |
| US20210070852A1 (en) | 2021-03-11 |
| JP2022547162A (ja) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002850A (es) | Formulaciones de anticuerpos anti-il-23p19. | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| AR069969A1 (es) | Formulacion liquida que contiene anticuerpo en alta concentracion | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| CL2017000208A1 (es) | Formulaciones de alta concentración de proteinas y anticuerpos (divisional de la solicitud n°142-2013) | |
| AR082171A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| AR075715A1 (es) | Formulacion de anticuerpo liofilizado | |
| ECSP088962A (es) | Nuevos herbicidas | |
| BRPI0918904B8 (pt) | formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma | |
| KR102231957B1 (ko) | 에텔칼세타이드(amg 416)의 안정한 액체 제형 | |
| AR040529A1 (es) | Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
| CO2023015509A2 (es) | Un método para mejorar la estabilidad de una formulación de anticuerpos | |
| MA43686B1 (fr) | Formulation liquide stable de gonadotrophines | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| US10314880B2 (en) | Composition comprising bortezomib | |
| AR125461A1 (es) | Células presentadoras de antígeno recombinante | |
| AR045258A1 (es) | Un producto farmaceutico para inyeccion | |
| EP3178927B1 (en) | Protein-stabilizing agent and protein-stabilizing method | |
| US20250186534A1 (en) | Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate | |
| AR122060A1 (es) | Formulaciones de anticuerpos anti-il-33 y métodos de uso de las mismas | |
| AR131269A1 (es) | Composición de la insulina asparta (variantes) |